Glizid 40 Tablet contains Gliclazide 40 mg, an oral hypoglycemic agent belonging to the sulfonylurea class, primarily indicated for the management of type 2 diabetes mellitus. Gliclazide functions by stimulating pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control in patients with non-insulin-dependent diabetes. This medication is typically prescribed when diet, exercise, and weight reduction alone are insufficient to achieve adequate blood glucose levels. Glizid 40 Tablet is effective in lowering both fasting and postprandial blood glucose concentrations, contributing to the prevention of long-term diabetic complications such as neuropathy, nephropathy, and retinopathy. It is important to administer Glizid 40 with meals to minimize the risk of hypoglycemia, a potential adverse effect characterized by symptoms such as dizziness, sweating, and confusion. Dosage adjustments should be individualized based on patient response and glycemic monitoring. Caution is advised in patients with hepatic or renal impairment, and it is contraindicated in individuals with type 1 diabetes, diabetic ketoacidosis, or hypersensitivity to sulfonylureas. Regular monitoring of blood glucose and HbA1c levels is recommended to assess therapeutic efficacy and safety. Glizid 40 Tablet should be used under medical supervision as part of a comprehensive diabetes management plan.